This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day for 21 days in ambulatory adult patients with genetically confirmed Charcot-Marie-Tooth disease Type 1 and Type 2.
October 2025 Update
NMD Pharma A/S has announced full enrollment in its Phase 2 SYNAPSE-CMT clinical trial, reaching this milestone ahead of schedule with 81 participants across sites in the United States and Europe. The study is evaluating the company’s investigational drug, NMD670, in CMT types 1 and 2. The company reports that data analysis will begin soon and expects to share trial results in early 2026.
